Agile Therapeutics Inc AGRX shares are trading lower by $2.30 (42 percent) at $2.70 in Wednesday's session.
The Street was not satisfied by its top-line results from its Phase 3 SECURE trial of Twirla. The company plans to resubmit results later in the first half of 2017.
After a much lower open ($1.93 vs. Tuesday's close of $5.00), shorts and new longs seized the opportunity and began to aggressively purchase shares of the issue. The current low of $1.83 far exceeds its former all-time low that was made in Tuesday's session at $4.46.
The issue has continued to make new highs for the session with the one standing at $2.77.
Today's price action is taking place on much higher than average volume. So far, 11 million shares have traded compared to its 20-day aver age of only 666,000.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.